Table 3. LINE-1 methylation level in early-onset colorectal cancer.
Clinical, pathological or molecular features | Total (n)* | Mean | Standard deviation | p-value |
Sex | ||||
Male | 61 | 60.93 | 6.598 | 0.092 |
Female | 54 | 58.87 | 6.422 | |
Age | ||||
>30 years | 91 | 60.26 | 6.757 | 0.345 |
<30 years | 24 | 58.83 | 5.791 | |
Body Mass Index (kg/m2) | ||||
<30 | 100 | 59.71 | 6.029 | 0.728 |
>30 | 10 | 60.4 | 5.337 | |
Family history of CRC1 | ||||
Yes | 16 | 59.68 | 6.005 | 0.246 |
No | 99 | 61.75 | 9.40 | |
Tumor location | ||||
Rectum | 47 | 58.3 | 6.54 | 0.026 |
Distal to splenic flexure | 35 | 60 | 5.46 | |
Proximal to splenic flexure | 33 | 62.3 | 7.12 | |
Synchronous or metachronous CRC | ||||
Yes | 5 | 64.2 | 6.76 | 0.141 |
No | 110 | 59.77 | 6.52 | |
TNM tumor stage | ||||
I–II | 40 | 59.63 | 6.054 | 0.687 |
III–IV | 75 | 60.15 | 6.861 | |
Tumor differentiation | ||||
Well or moderate | 97 | 60.03 | 6.555 | 0.926 |
Poor | 15 | 60.2 | 6.527 | |
Mucinous component | ||||
>50% | 39 | 61.41 | 5.959 | 0.096 |
<50% | 75 | 59.24 | 6.824 | |
Medullary growth pattern | ||||
Yes | 11 | 61.36 | 4.905 | 0.453 |
No | 103 | 59.79 | 6.748 | |
Crohńs reaction | ||||
Yes | 12 | 62.75 | 3.545 | 0.128 |
No | 98 | 59.63 | 6.908 | |
Tumor infiltrating lymphocytes | ||||
Yes | 26 | 60.88 | 5.443 | 0.447 |
No | 85 | 59.74 | 7.004 | |
Microsatellite instability | ||||
MSI | 25 | 59.72 | 6.717 | 0.454 |
MSS | 90 | 60.84 | 6.053 | |
Mismatch repair deficiency2 | ||||
Yes | 27 | 61.26 | 6.137 | 0.244 |
No | 88 | 59.7 | 6.680 |
P value was calculated by t-test.
Referred to patients with available information.
Including first and second degree relatives.
MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.